FDA Issues Emergency Use Authorization for Generic Over-the-Counter Drug to Treat New World Screwworm in Dogs and Cats

FDA Authorizes Generic Nitenpyram for New World Screwworm in Pets

The U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) on June 11, 2026, for generic Nitenpyram Tablets to treat New World screwworm (NWS) infestations in dogs, puppies, cats, and kittens weighing at least two pounds and four weeks old. This marks the first generic animal drug authorized for NWS, providing an affordable, fast-acting, over-the-counter treatment. The authorization is part of a broader government strategy to combat NWS, with the FDA having issued ten EUAs and three conditional approvals to date.

• Nitenpyram Tablets work rapidly, killing most NWS larvae within hours of the first dose, with a second dose recommended six hours later. Available over-the-counter in 11.4 mg and 57 mg tablet sizes, dosage is weight-based. The drug's effects are short-acting and do not prevent reinfestation, necessitating veterinary consultation for wound care and prevention strategies.
• This EUA is a key component of the U.S. government's aggressive strategy to stop the spread and eradicate New World screwworm. It follows an emergency declaration in August 2025 and is one of ten EUAs and three conditional approvals issued by the FDA to combat this threat, demonstrating a proactive and rapid regulatory response under the Trump administration.
• The authorization of generic Nitenpyram Tablets, sponsored by Felix Pharmaceuticals Pvt. Ltd. from Ireland, highlights the critical role of generic animal drugs in strengthening the domestic supply chain. This initiative expands the available veterinary drugs for NWS, reinforcing the FDA's commitment to providing timely and affordable options to safeguard animal health for American pet owners.

Integrating Generic Nitenpyram into NWS Treatment Guidelines

Current treatment approaches for New World screwworm (NWS) myiasis vary significantly between veterinary and human applications, with chemical control methods forming the foundation of most therapeutic strategies. In veterinary medicine, organophosphorus (OP) compounds and macrocyclic lactones represent the primary chemical interventions, with more recent adoption of spinosad-based foamy spray formulations demonstrated in Venezuela. These chemical approaches have been extensively implemented across endemic regions, with Brazil specifically utilizing organophosphate-based compounds as the primary control method for Cochliomyia hominivorax infestations.

For human myiasis cases, the standard of care emphasizes mechanical removal of larvae combined with appropriate antibiotic therapy for concurrent bacterial infections. A recent 2024 case report from Costa Rica documented successful treatment of a 71-year-old patient through extraction of approximately 160 first- and second-instar larvae, followed by ciprofloxacin administration to address concurrent Staphylococcus aureus and Pseudomonas aeruginosa infections. Complete ulcer healing was achieved following this combined approach of larval extraction and targeted antimicrobial therapy.

The economic burden and resistance concerns surrounding current treatment paradigms highlight significant challenges in NWS management. Control costs for larvicides alone have been estimated at US$2 million annually in Venezuela, while growing concerns about insecticide resistance to OP compounds have emerged due to improper and continuous chemical usage leading to selection pressure for resistant strains. These limitations underscore the need for alternative therapeutic approaches and resistance monitoring programs to ensure continued efficacy of current treatment guidelines.

Affordable Nitenpyram: Bolstering the Fight Against Screwworm Re-emergence

The recent Emergency Use Authorization (EUA) for generic Nitenpyram Tablets marks a pivotal moment in the ongoing battle against the New World screwworm (NWS). This fast-acting, over-the-counter treatment for pets is not merely a new drug; it represents a strategic enhancement to the nation's defenses against a persistent and economically damaging pest. Cochliomyia hominivorax, the fly responsible for NWS myiasis, is an obligate parasite that consumes living tissue in warm-blooded animals, including dogs, cats, livestock, wildlife, and even humans. Its re-emergence in the Florida Keys in 2016, after decades of successful eradication efforts, served as a stark reminder of its potential to reinvade and cause significant harm.

The availability of an affordable, generic option for pet owners is a game-changer. Studies indicate Nitenpyram achieves 100% larvicidal efficacy against C. hominivorax in dogs, offering a rapid response to infestations. This accessibility is crucial for several reasons:

• It empowers pet owners with an immediate, cost-effective tool to treat their animals, potentially preventing severe disease progression and reducing the need for costly veterinary interventions.

• By facilitating prompt treatment, it helps to reduce the overall parasite burden in the environment, thereby limiting the spread of NWS to other animals and supporting broader area-wide integrated pest management strategies.

However, this expanded access also introduces important considerations. The widespread, potentially less regulated use of an over-the-counter antiparasitic could, over time, contribute to the development of resistance in C. hominivorax populations. Furthermore, while Nitenpyram is highly effective against NWS, myiasis can be caused by various fly species, and misdiagnosis could lead to ineffective treatment for other conditions. It is also critical to remember that while this EUA addresses animal health, NWS remains a human health concern, with myiasis capable of acting as a vector for serious bacterial infections. Therefore, continued surveillance, public education, and a multi-faceted approach remain essential to effectively manage this re-emerging threat and protect both animal and human populations.